STEP-HFpEF DM
To evaluate the effect of semaglutide (GLP-1) in patients with obesity, Type II diabetes and chronic HFpEF on heart failure disease-specific symptoms, health status and quality of life, when compared with placebo
- Stadium
- klaar
- Middel
- semaglutide
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 13 augustus 2021
- Last Patient In
- 1 augustus 2022
- Last Patient Last Visit
- 24 augustus 2023
National Lead
dr. P van der Meer
Cardioloog
Studiedirecteur
dr. C.A. da Fonseca
Cardioloog
Contact Kantoor
